4.24
price up icon6.80%   0.27
after-market After Hours: 4.19 -0.05 -1.18%
loading
Urogen Pharma Ltd stock is traded at $4.24, with a volume of 2.90M. It is up +6.80% in the last 24 hours and down -60.59% over the past month. UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
See More
Previous Close:
$3.97
Open:
$3.97
24h Volume:
2.90M
Relative Volume:
2.64
Market Cap:
$195.51M
Revenue:
$82.71M
Net Income/Loss:
$-102.24M
P/E Ratio:
-1.1553
EPS:
-3.67
Net Cash Flow:
$-76.57M
1W Performance:
+1.19%
1M Performance:
-60.59%
6M Performance:
-66.61%
1Y Performance:
-68.71%
1-Day Range:
Value
$3.605
$4.24
1-Week Range:
Value
$3.605
$4.25
52-Week Range:
Value
$3.42
$20.70

Urogen Pharma Ltd Stock (URGN) Company Profile

Name
Name
Urogen Pharma Ltd
Name
Phone
972 9 770 7601
Name
Address
9 HA'TA'ASIYA ST, RA'ANANA
Name
Employee
234
Name
Twitter
@UroGenPharma
Name
Next Earnings Date
2025-03-10
Name
Latest SEC Filings
Name
URGN's Discussions on Twitter

Compare URGN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
URGN
Urogen Pharma Ltd
4.24 193.19M 82.71M -102.24M -76.57M -3.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades

Date Action Analyst Rating Change
May-22-25 Downgrade H.C. Wainwright Buy → Neutral
Apr-16-25 Initiated Scotiabank Sector Outperform
Feb-19-25 Resumed Ladenburg Thalmann Buy
Aug-22-24 Initiated Guggenheim Buy
Feb-08-23 Downgrade Jefferies Buy → Hold
Apr-27-22 Initiated Berenberg Buy
Apr-16-20 Reiterated H.C. Wainwright Buy
Apr-13-20 Reiterated H.C. Wainwright Buy
Jan-09-20 Initiated National Securities Neutral
May-30-19 Initiated JP Morgan Neutral
May-29-19 Initiated Goldman Neutral
Jan-29-19 Initiated H.C. Wainwright Buy
Nov-08-18 Resumed Jefferies Buy
Apr-04-18 Upgrade Raymond James Mkt Perform → Outperform
Jan-02-18 Initiated Ladenburg Thalmann Buy
Nov-15-17 Reiterated Oppenheimer Outperform
Nov-15-17 Downgrade Raymond James Outperform → Mkt Perform
View All

Urogen Pharma Ltd Stock (URGN) Latest News

pulisher
May 31, 2025

Class Action Lawsuit Filed: UroGen Pharma Ltd. (URGN)Join by July 28, 2025Contact Levi & Korsinsky - ACCESS Newswire

May 31, 2025
pulisher
May 31, 2025

URGN CLASS ACTION NOTICE: UroGen Pharma Ltd. has been Sued - GlobeNewswire

May 31, 2025
pulisher
May 30, 2025

Levi & Korsinsky Investigates UroGen Pharma Ltd. (URGN) Over Possible Securities Fraud - ACCESS Newswire

May 30, 2025
pulisher
May 30, 2025

Pharma Co. Hid Cancer Study Method Problems, Investor Claims - Law360

May 30, 2025
pulisher
May 30, 2025

URGN ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of UroGen Pharma Ltd. Investors - Business Wire

May 30, 2025
pulisher
May 30, 2025

URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

May 30, 2025
pulisher
May 30, 2025

URGN Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against ... - Eagle-Tribune

May 30, 2025
pulisher
May 30, 2025

URGN FRAUD ALERT: UroGen Pharma Ltd. Investors are Alerted to Contact BFA Law about the Pending Securities Fraud Class Action - Newsfile

May 30, 2025
pulisher
May 30, 2025

URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire

May 30, 2025
pulisher
May 30, 2025

UroGen Pharma Ltd. (URGN) Faces Securities Class Action - GlobeNewswire

May 30, 2025
pulisher
May 30, 2025

URGN BREAKING NEWS: UroGen Pharma Ltd. Stock Plummets 45% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NASDAQ:URGN) - Business Wire

May 30, 2025
pulisher
May 30, 2025

UroGen Investor Sues After Cancer Therapy Setback, 45% Selloff - Bloomberg Law News

May 30, 2025
pulisher
May 30, 2025

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against UroGen Pharma Ltd. (URGN) - GlobeNewswire Inc.

May 30, 2025
pulisher
May 30, 2025

INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire

May 30, 2025
pulisher
May 30, 2025

URGN Investors Have the Opportunity to Lead the UroGen Pharma Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - PR Newswire

May 30, 2025
pulisher
May 30, 2025

UroGen Pharma Ltd. (NASDAQ:URGN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

May 30, 2025
pulisher
May 29, 2025

URGN Stockholder Alert: Robbins LLP Informs Investors of the UroGen Pharma Ltd. Class Action Lawsuit - Morningstar

May 29, 2025
pulisher
May 29, 2025

UroGen Pharma Ltd. Investors: Please contact the Portnoy - GlobeNewswire

May 29, 2025
pulisher
May 29, 2025

URGN INVESTOR ALERT: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company AnnouncementFT.com - Financial Times

May 29, 2025
pulisher
May 29, 2025

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen - Business Wire

May 29, 2025
pulisher
May 29, 2025

Law Offices of Howard G. Smith Encourages UroGen Pharma Ltd. (URGN) Investors To Inquire About Securities Fraud Class Action - Business Wire

May 29, 2025
pulisher
May 29, 2025

UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

May 29, 2025
pulisher
May 29, 2025

Did You Suffer Losses in UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire

May 29, 2025
pulisher
May 29, 2025

UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor ScrutinyHagens Berman - PR Newswire

May 29, 2025
pulisher
May 28, 2025

Did UroGen Pharma Ltd. (URGN) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire

May 28, 2025
pulisher
May 28, 2025

Oppenheimer maintains Outperform on UroGen Pharma stock By Investing.com - Investing.com India

May 28, 2025
pulisher
May 27, 2025

Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire

May 27, 2025
pulisher
May 27, 2025

UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA - New Castle News

May 27, 2025
pulisher
May 27, 2025

UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA’s - GlobeNewswire

May 27, 2025
pulisher
May 27, 2025

UroGen Pharma Ltd. (NASDAQ:URGN) Stock Position Decreased by Millennium Management LLC - Defense World

May 27, 2025
pulisher
May 26, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against UroGen Pharma Ltd. (URGN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

May 26, 2025
pulisher
May 26, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd.URGN - PR Newswire

May 26, 2025
pulisher
May 26, 2025

Janus Henderson Group PLC Acquires New Stake in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World

May 26, 2025
pulisher
May 26, 2025

Lazard Asset Management LLC Acquires New Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World

May 26, 2025
pulisher
May 26, 2025

Q2 EPS Estimates for UroGen Pharma Raised by HC Wainwright - Defense World

May 26, 2025
pulisher
May 25, 2025

UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug - Benzinga

May 25, 2025
pulisher
May 25, 2025

Guggenheim Has Lowered Expectations for UroGen Pharma (NASDAQ:URGN) Stock Price - Defense World

May 25, 2025
pulisher
May 25, 2025

The Goldman Sachs Group Cuts UroGen Pharma (NASDAQ:URGN) Price Target to $3.00 - Defense World

May 25, 2025
pulisher
May 24, 2025

Ongoing Investigation: UroGen Pharma Ltd. (URGN) May Have Misled ShareholdersLevi & Korsinsky Investigates - ACCESS Newswire

May 24, 2025
pulisher
May 24, 2025

Northern Trust Corp Purchases 23,345 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World

May 24, 2025
pulisher
May 24, 2025

Kaplan Fox Reminds Investors of UroGen Pharma Ltd. (URGN) to an Investigation of Potential Securities Law Violations - FinancialContent

May 24, 2025
pulisher
May 23, 2025

Guggenheim's Michael Schmidt Lowers Price Target for UroGen Pharma (URGN) | URGN Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Kaplan Fox is Investigating Potential Securities Law Violations against UroGen Pharma Ltd. (URGN) - FinancialContent

May 23, 2025
pulisher
May 23, 2025

UroGen Pharma (URGN) Price Target Cut by Guggenheim | URGN Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

URGN ACTIVE INVESTIGATION: Lost Money on UroGen Pharma Ltd.? Contact Levi & Korsinsky Now - ACCESS Newswire

May 23, 2025
pulisher
May 23, 2025

UroGen crashes as FDA AdCom rebukes bladder cancer drug - MSN

May 23, 2025
pulisher
May 22, 2025

UroGen Pharma Shares Fall After HC Wainwright Downgrade - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Kaplan Fox Announces an Investigation Into UroGen Pharma Ltd. (URGN) for Potential Securities Law Violations - FinancialContent

May 22, 2025
pulisher
May 22, 2025

UroGen Pharma (URGN) Target Price Slashed by Goldman Sachs | URGN Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Goldman Sachs cuts UroGen Pharma target to $3 from $16 - Investing.com Australia

May 22, 2025
pulisher
May 22, 2025

UroGen tanks as FDA panel vote goes against UGN-102 - The Pharma Letter

May 22, 2025

Urogen Pharma Ltd Stock (URGN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Cap:     |  Volume (24h):